

# Fabrizio De Ponti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2570753/publications.pdf>

Version: 2024-02-01

249  
papers

8,716  
citations

44042

48  
h-index

60583

81  
g-index

253  
all docs

253  
docs citations

253  
times ranked

9165  
citing authors

#	ARTICLE	IF	CITATIONS
1	Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 247-255.	3.3	18
2	Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems. <i>Journal of Nephrology</i> , 2022, 35, 1017-1027.	0.9	4
3	Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 303-320.	0.9	1
4	The European Prescribing Exam: assessing whether European medical students can prescribe rationally and safely. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1049-1051.	0.8	7
5	Impact of nephrotoxic drugs on urinary biomarkers of renal function in very preterm infants. <i>Pediatric Research</i> , 2022, 91, 1715-1722.	1.1	5
6	Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. <i>Drug Safety</i> , 2022, 45, 663-673.	1.4	7
7	Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 727-736.	1.0	15
8	Liver Injury with Nintedanib: A Pharmacovigilanceâ€“Pharmacokinetic Appraisal. <i>Pharmaceuticals</i> , 2022, 15, 645.	1.7	5
9	Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e120-e120.	0.5	15
10	Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 983-989.	0.8	29
11	Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVIDâ€“19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1533-1540.	1.1	40
12	SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 647-650.	0.9	1
13	Assessment of adverse reactions to Î±-lipoic acid containing dietary supplements through spontaneous reporting systems. <i>Clinical Nutrition</i> , 2021, 40, 1176-1185.	2.3	18
14	Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 199-205.	1.3	10
15	Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 219-227.	1.1	59
16	Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 233-239.	0.8	23
17	Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1169-1176.	1.3	8
18	Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. <i>Pharmaceutics</i> , 2021, 13, 302.	2.0	24

#	ARTICLE	IF	CITATIONS
19	Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies. <i>CNS Drugs</i> , 2021, 35, 345-384.	2.7	8
20	Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. <i>Cancers</i> , 2021, 13, 1758.	1.7	19
21	European List of Essential Medicines for Medical Education: a protocol for a modified Delphi study. <i>BMJ Open</i> , 2021, 11, e045635.	0.8	5
22	Fluoroquinolones and Aortic Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 881.	2.6	0
23	Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1421-1431.	1.0	9
24	Developing medical artificial intelligence leaders: International university consortium approach. <i>Medical Education</i> , 2021, 55, 1321-1322.	1.1	2
25	Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System. <i>Frontiers in Pharmacology</i> , 2021, 12, 740707.	1.6	5
26	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. <i>Acta Diabetologica</i> , 2020, 57, 71-80.	1.2	18
27	Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with caution. <i>Acta Diabetologica</i> , 2020, 57, 115-116.	1.2	4
28	Reduced neuropsychiatric events as "beneficial reactions" to drugs: Seek associations with caution. <i>Brain, Behavior, and Immunity</i> , 2020, 84, 275-276.	2.0	4
29	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020, 15, 449-466.	1.7	86
30	Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. <i>Drug Safety</i> , 2020, 43, 1277-1285.	1.4	25
31	Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1367-1369.	1.0	11
32	Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors. <i>In Vivo</i> , 2020, 34, 1333-1339.	0.6	9
33	Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review. <i>European Journal of Internal Medicine</i> , 2020, 75, 60-70.	1.0	25
34	Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database. <i>Aging</i> , 2020, 12, 19711-19739.	1.4	13
35	Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements. <i>Clinical Nutrition</i> , 2020, 39, 3854-3855.	2.3	1
36	Drug-induced Kounis syndrome: A matter of pharmacovigilance. <i>International Journal of Cardiology</i> , 2019, 274, 381.	0.8	9

#	ARTICLE	IF	CITATIONS
37	µ-opioid receptor, ²endorphin, and cannabinoid receptor are increased in the colonic mucosa of irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13688.	1.6	25
38	Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. <i>Frontiers in Pharmacology</i> , 2019, 10, 1235.	1.6	24
39	Relationship between adverse drug reactions to antibacterial agents and the <i>Klebsiella pneumoniae</i> carbapenemase-producing (KPC) <i>Klebsiella pneumoniae</i> outbreak: insight from a pharmacovigilance study. <i>BMC Pharmacology &amp; Toxicology</i> , 2019, 20, 65.	1.0	5
40	Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. <i>Drug Safety</i> , 2019, 42, 1409-1422.	1.4	13
41	Severe quetiapine voluntary overdose successfully treated with a new hemoperfusion sorbent. <i>International Journal of Artificial Organs</i> , 2019, 42, 516-520.	0.7	13
42	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1087-1090.	0.9	4
43	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019, 14, 205-221.	1.7	72
44	Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres. <i>PLoS ONE</i> , 2019, 14, e0211938.	1.1	3
45	Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. <i>Oncologist</i> , 2019, 24, e1228-e1231.	1.9	30
46	Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000725.	1.2	26
47	Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1633-1640.	1.4	21
48	Ex vivo effect of vascular wall stromal cells secretome on enteric ganglia. <i>World Journal of Gastroenterology</i> , 2019, 25, 4892-4903.	1.4	4
49	Hepatitis B vaccination and the putative risk of central demyelinating diseases – A systematic review and meta-analysis. <i>Vaccine</i> , 2018, 36, 1548-1555.	1.7	37
50	Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems. <i>Drug Safety</i> , 2018, 41, 745-752.	1.4	24
51	Human papillomavirus vaccine and demyelinating diseases – A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2018, 132, 108-118.	3.1	32
52	Advancements in drug development for diarrhea-predominant irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 251-263.	1.9	6
53	No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase. <i>Expert Review of Vaccines</i> , 2018, 17, 363-381.	2.0	7
54	ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. <i>Internal and Emergency Medicine</i> , 2018, 13, 1-9.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1903-1914.	0.9	18
56	Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System. <i>International Journal of Cardiology</i> , 2018, 273, 183-186.	0.8	78
57	Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 869-874.	1.0	10
58	Gender-differences of in vitro colonic motility after chemo- and radiotherapy in humans. <i>BMC Pharmacology &amp; Toxicology</i> , 2018, 19, 49.	1.0	2
59	Observational research on sodium glucose co-transporter <sup>2</sup> inhibitors: A real breakthrough?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2711-2723.	2.2	18
60	Recurrence of pericarditis after influenza vaccination: a case report and review of the literature. <i>BMC Pharmacology &amp; Toxicology</i> , 2018, 19, 20.	1.0	22
61	ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations – authors' reply. <i>Internal and Emergency Medicine</i> , 2018, 13, 635-636.	1.0	5
62	Reporting of immune checkpoint inhibitor-associated myocarditis. <i>Lancet, The</i> , 2018, 392, 383.	6.3	9
63	Association between the use of proton pump inhibitors and cardiovascular events: A note of caution. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12977.	1.6	1
64	Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 555-565.	1.5	8
65	Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping. <i>Drug Safety</i> , 2017, 40, 823-834.	1.4	6
66	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. <i>Pharmacological Research</i> , 2017, 120, 206-218.	3.1	11
67	Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice. <i>Drug Safety</i> , 2017, 40, 461-464.	1.4	10
68	Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-infective Agents: A Systematic Literature Review From the ARITMO Project. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 558-572.	1.0	11
69	Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. <i>Internal and Emergency Medicine</i> , 2017, 12, 923-934.	1.0	4
70	Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit. <i>Italian Journal of Pediatrics</i> , 2017, 43, 37.	1.0	15
71	Liver injury with direct-acting anticoagulants: has the fog cleared?. <i>Heart</i> , 2017, 103, 2010-2010.	1.2	3
72	Drug-induced liver injury: Towards early prediction and risk stratification. <i>World Journal of Hepatology</i> , 2017, 9, 30.	0.8	22

#	ARTICLE	IF	CITATIONS
73	Authors'™ reply to Tufan and colleagues and Boucaud-Maitre. <i>BMJ, The</i> , 2016, 353, i3188.	3.0	0
74	Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 487-497.	1.1	27
75	Stroke, Migraine and Triptans: From Bedside to Bench. <i>EBioMedicine</i> , 2016, 6, 14-15.	2.7	1
76	Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 380-386.	1.1	30
77	Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2016, 150, 1319-1331.e20.	0.6	26
78	Safety Meta-Analysis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2193.	1.2	4
79	Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. <i>Drug Safety</i> , 2016, 39, 1175-1187.	1.4	31
80	Switching among Equivalents in Chronic Cardiovascular Therapies: "Real World"™ Data from Italy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 63-69.	1.2	1
81	Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. <i>BMJ, The</i> , 2016, 353, i2231.	3.0	70
82	Drug utilization research and pharmacovigilance. , 2016, , 399-407.		2
83	The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. <i>Drug Safety</i> , 2016, 39, 59-68.	1.4	25
84	Authors'™ Reply to Alain Brillon's™ Comment on "The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project". <i>Drug Safety</i> , 2016, 39, 367-368.	1.4	0
85	Appropriateness of Proton Pump Inhibitor prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy. <i>European Journal of Internal Medicine</i> , 2016, 30, 31-36.	1.0	23
86	Advising Mothers on the Use of Medications during Breastfeeding. <i>Journal of Human Lactation</i> , 2016, 32, 15-19.	0.8	24
87	Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 552-561.	0.3	10
88	Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology. <i>World Journal of Gastroenterology</i> , 2016, 22, 9057.	1.4	9
89	Clinically important drug-drug interactions in poly-treated elderly outpatients: a campaign to improve appropriateness in general practice. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1411-1420.	1.1	27
90	Social and Clinical Descriptors of Antipsychotic Prescription. <i>International Journal of Psychiatry in Medicine</i> , 2015, 49, 45-62.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Nerve Fiber Outgrowth Is Increased in the Intestinal Mucosa of Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2015, 148, 1002-1011.e4.	0.6	127
92	Detection of D-phenylalanine in skin lesions in a case of dermal elastosis after a previous long-term treatment for Wilson's disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 383-386.	1.3	14
93	Comment on: "Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus": <i>Clinical Pharmacokinetics</i> , 2015, 54, 447-448.	1.6	4
94	Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 285-293.	1.1	66
95	Posterior Reversible Encephalopathy Syndrome Associated With Licorice Consumption: A Case Report in a 10-Year-Old Boy. <i>Pediatric Neurology</i> , 2015, 52, 457-459.	1.0	10
96	609 Increased Expression of $\mu$ -opioid and Cannabinoid Receptors in the Colonic Mucosa of Patients With Irritable Bowel Syndrome (IBS). <i>Gastroenterology</i> , 2015, 148, S-119.	0.6	0
97	Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection. <i>Drug Safety</i> , 2015, 38, 535-551.	1.4	29
98	Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies. <i>Cephalalgia</i> , 2015, 35, 118-131.	1.8	115
99	Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe. <i>PLoS ONE</i> , 2015, 10, e0119551.	1.1	49
100	Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. <i>World Journal of Hepatology</i> , 2015, 7, 1761.	0.8	40
101	Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 293-305.	1.5	17
102	Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 262.	3.7	6
103	Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 617-625.	0.8	12
104	Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. <i>World Journal of Hepatology</i> , 2014, 6, 601.	0.8	59
105	Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2095-2101.	0.8	30
106	Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 715-720.	0.8	6
107	Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. <i>Drug Safety</i> , 2013, 36, 467-479.	1.4	61
108	The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. <i>Acta Diabetologica</i> , 2013, 50, 569-577.	1.2	101

#	ARTICLE	IF	CITATIONS
109	Animal models of chemically induced intestinal inflammation: Predictivity and ethical issues. , 2013, 139, 71-86.		41
110	Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 443-445.	0.9	5
111	Global Perspectives in Pharmacovigilance. <i>Journal of Pharmacovigilance</i> , 2013, 01, .	0.2	0
112	Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2013, 4, 7.	1.6	28
113	Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe. <i>PLoS ONE</i> , 2013, 8, e81208.	1.1	45
114	Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective. <i>Current Medicinal Chemistry</i> , 2013, 21, 417-436.	1.2	109
115	Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. <i>Neurogastroenterology and Motility</i> , 2012, 24, 1118.	1.6	62
116	Academic output from EU-funded health research projects. <i>Lancet, The</i> , 2012, 380, 1903-1904.	6.3	4
117	Portal hypertension and liver cirrhosis in rats: effect of the $\beta_3$ -adrenoceptor agonist SR58611A. <i>British Journal of Pharmacology</i> , 2012, 167, 1137-1147.	2.7	17
118	Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. <i>Internal and Emergency Medicine</i> , 2012, 7, 113-131.	1.0	49
119	Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2011, 106, 1290-1298.	0.2	179
120	Colonic Mucosal Mediators From Patients With Irritable Bowel Syndrome Excite Guinea Pig Enteric Cholinergic Motor Neurons via Purinergic, Prostaglandin, and TRPV1 Pathways. <i>Gastroenterology</i> , 2011, 140, S-129.	0.6	1
121	Mucosal Neuroplasticity and Its Correlation With Symptoms in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2011, 140, S-369.	0.6	0
122	Effect of $\beta_2$ -Casomorphins on Intestinal Propulsion in the Guinea-pig Colon. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 41, 302-305.	1.2	8
123	Opioid pathways exert a tonic restraint in the guinea-pig isolated colon: changes after chronic sympathetic denervation. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 45, 668-670.	1.2	7
124	[ $^3$ H]Acetylcholine Release from the Guinea-pig Distal Colon: Comparison with Ileal [ $^3$ H]Acetylcholine Release and Effect of Adrenoceptor Stimulation. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 41, 824-828.	1.2	9
125	Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling. <i>Current Drug Targets</i> , 2011, 12, 263-286.	1.0	11
126	Effect of Calcium Channel Blockers on Postprandial Gastrointestinal Motility in the Dog. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 44, 227-230.	1.2	4



#	ARTICLE	IF	CITATIONS
127	Inhibition of Endogenous Acetylcholine Release by Blockade of Voltage-dependent Calcium Channels in Enteric Neurons of the Guinea-pig Colon. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 45, 449-452.	1.2	13
128	QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 839-841.	1.1	7
129	Excipients in medicinal products used in gastroenterology as a possible cause of side effects. <i>Regulatory Toxicology and Pharmacology</i> , 2011, 60, 93-105.	1.3	45
130	Gender- and Age-Related Differences in Muscular and Nerve-Mediated Responses in Human Colon. <i>Digestive Diseases and Sciences</i> , 2011, 56, 352-358.	1.1	7
131	Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 407-414.	0.8	23
132	Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. , 2010, 125, 196-218.		126
133	Role of drugs and devices in patients at risk of sudden cardiac death. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 575-594.	1.0	15
134	Proinflammatory role of vasopressin through V1b receptors in hapten-induced experimental colitis in rodents: implication in IBD. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G1298-G1307.	1.6	18
135	Antimicrobials and the Risk of Torsades de Pointes. <i>Drug Safety</i> , 2010, 33, 303-314.	1.4	108
136	Non-peptidyl low molecular weight radical scavenger IAC attenuates DSS-induced colitis in rats. <i>World Journal of Gastroenterology</i> , 2010, 16, 3642.	1.4	23
137	Protection from DNBS-induced colitis by the tachykinin NK1 receptor antagonist SR140333 in rats. <i>European Journal of Pharmacology</i> , 2009, 603, 133-137.	1.7	13
138	Effects of the non-peptidyl low molecular weight radical scavenger IAC in DNBS-induced colitis in rats. <i>European Journal of Pharmacology</i> , 2009, 614, 137-145.	1.7	13
139	Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 512-518.	0.9	121
140	Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 88-98.	1.1	17
141	The $\beta_3$ -adrenoceptor as a therapeutic target: Current perspectives. <i>Pharmacological Research</i> , 2009, 59, 221-234.	3.1	143
142	hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1005-1021.	1.5	70
143	The $\beta_3$ -adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. <i>Neurogastroenterology and Motility</i> , 2008, 20, 1030-1041.	1.6	44
144	The hERG K <sup>+</sup> channel: target and antitarget strategies in drug development. <i>Pharmacological Research</i> , 2008, 57, 181-195.	3.1	131

#	ARTICLE	IF	CITATIONS
145	Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia. <i>Current Medicinal Chemistry</i> , 2008, 15, 2472-2517.	1.2	6
146	Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. <i>Neurogastroenterology and Motility</i> , 2007, 19, 89-119.	1.6	53
147	Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 346-355.	1.1	30
148	Publication of a negative trial without disclosing the drug. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1247-1249.	1.9	1
149	Pharmacological and Pharmacokinetic Aspects of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1421-1434.	0.6	33
150	Generic versus brand-name medicinal products: Are they really interchangeable?. <i>Digestive and Liver Disease</i> , 2006, 38, 560-562.	0.4	5
151	Enteric neuroplasticity evoked by inflammation. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2006, 126-127, 264-272.	1.4	185
152	An update on the first decade of the European centralized procedure: how many innovative drugs?. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 610-616.	1.1	55
153	Gastro-intestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 235-241.	0.8	11
154	Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 938-945.	1.3	34
155	Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 475-478.	1.1	47
156	QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development. <i>Medicinal Research Reviews</i> , 2005, 25, 133-166.	5.0	258
157	QT Prolongation Through hERG K+ Channel Blockade: Current Knowledge and Strategies for the Early Prediction During Drug Development. <i>ChemInform</i> , 2005, 36, no.	0.1	1
158	Initial treatment of hypertension and adherence to therapy in general practice in Italy. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 603-609.	0.8	43
159	Idiopathic dyspepsia. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 175-183.	0.3	2
160	5-HT7 Receptors Modulate Peristalsis and Accommodation in the Guinea Pig Ileum. <i>Gastroenterology</i> , 2005, 129, 1557-1566.	0.6	66
161	Effect of muscarinic receptor blockade on canine gastric tone and compliance in vivo. <i>Pharmacological Research</i> , 2005, 51, 289-296.	3.1	8
162	Pharmacology of serotonin: what a clinician should know. <i>Gut</i> , 2004, 53, 1520-1535.	6.1	121

#	ARTICLE	IF	CITATIONS
163	Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 379-390.	1.9	238
164	Diagnosis and therapy of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 10-22.	1.9	37
165	Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement. <i>European Journal of Clinical Pharmacology</i> , 2004, 59, 825-831.	0.8	35
166	Pattern of NSAID use in the Italian general population: a questionnaire-based survey. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 731-738.	0.8	54
167	Delayed gastric emptying in functional dyspepsia. <i>Current Treatment Options in Gastroenterology</i> , 2004, 7, 259-264.	0.3	13
168	Inflammatory neuropathies of the enteric nervous system. <i>Gastroenterology</i> , 2004, 126, 1872-1883.	0.6	265
169	Triptans and gastric accommodation: pharmacological and therapeutic aspects. <i>Digestive and Liver Disease</i> , 2004, 36, 85-92.	0.4	20
170	Colonic smooth muscle responses in patients with diverticular disease of the colon: effect of the NK2 receptor antagonist SR48968. <i>Digestive and Liver Disease</i> , 2004, 36, 348-354.	0.4	32
171	Antibacterial macrolides: a drug class with a complex pharmacological profile. <i>Pharmacological Research</i> , 2004, 50, 211-222.	3.1	48
172	Progress with Novel Pharmacological Strategies for Gastro-oesophageal Reflux Disease. <i>Drugs</i> , 2004, 64, 347-361.	4.9	21
173	Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by $\alpha_2$ -adrenoceptors in the presence of experimental colitis. <i>British Journal of Pharmacology</i> , 2003, 139, 309-320.	2.7	74
174	The influence of surgery, immunosuppressive drugs, and rejection, on graft function after small bowel transplantation: a large-animal study. <i>Transplant International</i> , 2003, 16, 327-335.	0.8	11
175	$\alpha_3$ -adrenoceptor stimulation ameliorates experimental colitis in rats. <i>Gastroenterology</i> , 2003, 124, A347.	0.6	0
176	Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. <i>Gastroenterology</i> , 2003, 125, 70-79.	0.6	118
177	Anti-neuronal antibodies in patients with celiac disease and neurological disorders. <i>Gastroenterology</i> , 2003, 124, A15.	0.6	1
178	Identification of galanin receptor 1 on ascending excitatory pathways: Immunohistochemical and functional evidence. <i>Gastroenterology</i> , 2003, 124, A138-A139.	0.6	0
179	New Developments in the Treatment of Functional Dyspepsia. <i>Drugs</i> , 2003, 63, 869-892.	4.9	37
180	5-HT4 Receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract. <i>Digestive and Liver Disease</i> , 2003, 35, 244-250.	0.4	15

#	ARTICLE	IF	CITATIONS
181	Review of the implications of dietary tryptophan intake in patients with irritable bowel syndrome and psychiatric disorders. <i>Digestive and Liver Disease</i> , 2003, 35, 590-595.	0.4	28
182	Novel therapeutic strategies in acid-related disorders. <i>Expert Opinion on Therapeutic Patents</i> , 2003, 13, 639-649.	2.4	15
183	Role of 5-HT1B/D receptors in canine gastric accommodation: effect of sumatriptan and 5-HT1B/D receptor antagonists. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, G96-G104.	1.6	24
184	Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. <i>American Journal of Gastroenterology</i> , 2002, 97, 2454-2459.	0.2	91
185	Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. <i>American Journal of Gastroenterology</i> , 2002, 97, 2454-2459.	0.2	76
186	NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND INFLAMMATORY BOWEL DISEASE: CURRENT PERSPECTIVES. <i>Pharmacological Research</i> , 2002, 46, 1-6.	3.1	64
187	Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes. <i>Drug Safety</i> , 2002, 25, 263-286.	1.4	291
188	Clinical Findings and Anti-Neuronal Antibodies in Coeliac Disease with Neurological Disorders. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 1276-1281.	0.6	64
189	Role of tachykinergic and cholinergic pathways in modulating canine gastric tone and compliance in vivo. <i>Pharmacological Research</i> , 2002, 45, 341-347.	3.1	15
190	Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+Channel Blockers. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3844-3853.	2.9	409
191	Use of anti-asthmatic drugs in Italy: analysis of prescriptions in general practice in the light of guidelines for asthma treatment. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 55-59.	0.8	6
192	The cathartic colon?. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 643-644.	1.9	7
193	Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 171-177.	1.1	39
194	Treatment functional GI disease: the complex pharmacology of serotonergic drugs. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 680-680.	1.1	3
195	Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes. , 2002, 25, 263.		1
196	Methylnaltrexone Progenics. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 614-20.	2.3	4
197	Tachykinin-dependent and -independent components of peristalsis in the guinea pig isolated distal colon. <i>Gastroenterology</i> , 2001, 120, 938-945.	0.6	53
198	Irritable Bowel Syndrome. <i>Drugs</i> , 2001, 61, 317-332.	4.9	128

#	ARTICLE	IF	CITATIONS
199	Gastric motor effects of triptans: open questions and future perspectives. <i>Pharmacological Research</i> , 2001, 43, 205-210.	3.1	24
200	Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 185-209.	0.8	169
201	The pharmacological treatment of acute colonic pseudo-obstruction. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1717-1727.	1.9	96
202	Intestinal motor stimulation by the 5-HT <sub>4</sub> receptor agonist ML10302: differential involvement of tachykinergic pathways in the canine small bowel and colon. <i>Neurogastroenterology and Motility</i> , 2001, 13, 543-553.	1.6	20
203	QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 1-18.	0.8	236
204	QTc and psychotropic drugs. <i>Lancet</i> , The, 2000, 356, 75-76.	6.3	39
205	Correlations between functional changes and different grades of acute rejection in swine small bowel allografts. <i>Transplantation Proceedings</i> , 2000, 32, 1250-1251.	0.3	5
206	Reduced Bcl-2 expression in the enteric nervous system (ENS) as a marker for neural degeneration in patients with gastrointestinal motor disorders (GIMD). <i>Gastroenterology</i> , 2000, 118, A867.	0.6	11
207	Review article: cardiac adverse effects of gastrointestinal prokinetics. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1585-1591.	1.9	157
208	ATYPICAL $\hat{\imath}^2$ -ADRENOCEPTORS MEDIATING RELAXATION IN THE HUMAN COLON: FUNCTIONAL EVIDENCE FOR $\hat{\imath}^3$ -RATHER THAN $\hat{\imath}^4$ -ADRENOCEPTORS. <i>Pharmacological Research</i> , 1999, 39, 345-348.	3.1	17
209	Modulation of enteric cholinergic neurons by hetero- and autoreceptors: Cooperation among inhibitory inputs. <i>Life Sciences</i> , 1999, 65, 813-821.	2.0	12
210	Plasticity in the enteric nervous system. <i>Gastroenterology</i> , 1999, 117, 1438-1458.	0.6	149
211	Functional Gut Disorders. , 1998, 80, 49-88.		67
212	Peripheral Benzodiazepine Receptor Expression on Leukocytes and Neutrophil Function during Anticonvulsant Monotherapy. <i>Pharmacology</i> , 1998, 57, 215-221.	0.9	12
213	Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression. <i>Transplantation Proceedings</i> , 1997, 29, 691-692.	0.3	5
214	Small bowel myoelectrical activity after transplantation in pigs: Motility versus ACR score. <i>Transplantation Proceedings</i> , 1997, 29, 1809-1810.	0.3	0
215	Pharmacological criteria for the detection of $\hat{\imath}^3$ -adrenoceptors. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 52.	4.0	2
216	Acetylcholine detection by a modified HPLC-ED method improves the assessment of cholinergic function in the myenteric plexus of the guinea-pig colon. <i>Neuroscience Letters</i> , 1997, 232, 9-12.	1.0	12

#	ARTICLE	IF	CITATIONS
217	In vivo Characterization of the Colonic Prokinetic Effect of Erythromycin in the Rabbit. <i>Pharmacology</i> , 1997, 54, 64-75.	0.9	22
218	Effects of Carbamazepine on Human PMN Function: Possible Role of Peripheral Benzodiazepine Receptors. <i>Annals of the New York Academy of Sciences</i> , 1997, 832, 130-134.	1.8	3
219	Absence of histamine H3-receptors in the rabbit colon: Species difference. <i>General Pharmacology</i> , 1997, 29, 217-221.	0.7	8
220	Functional evidence of atypical $\hat{1}^2_3$ -adrenoceptors in the human colon using the $\hat{1}^2_3$ -selective adrenoceptor antagonist, SR 59230A. <i>British Journal of Pharmacology</i> , 1996, 117, 1374-1376.	2.7	60
221	Adrenergic mechanisms in the control of gastrointestinal motility: From basic science to clinical applications. , 1996, 69, 59-78.		75
222	Functional Evidence for the Presence of $\beta_3$ -Adrenoceptors in the Guinea Pig Common Bile Duct and Colon. <i>Pharmacology</i> , 1995, 51, 288-297.	0.9	19
223	Tonic modulation of neurotransmitter release in the guinea-pig myenteric plexus: effect of $\hat{1}^2_4$ and $\hat{1}^e$ opioid receptor blockade and of chronic sympathetic denervation. <i>Neuroscience Letters</i> , 1995, 194, 185-188.	1.0	20
224	N-Methyl-di-aspartate receptors modulate neurotransmitter release and peristalsis in the guinea pig isolated colon. <i>Neuroscience Letters</i> , 1995, 183, 139-142.	1.0	49
225	Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of $\hat{1}^2_3$ -adrenoceptors. <i>British Journal of Pharmacology</i> , 1995, 114, 1447-1453.	2.7	17
226	Effect of desipramine-induced blockade of neuronal uptake mechanisms on adrenoceptor-mediated responses in the guinea-pig colon. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1994, 350, 499-506.	1.4	9
227	Profile of the New ACE Inhibitor Trandolapril (RU 44570). <i>Cardiovascular Drug Reviews</i> , 1994, 12, 317-333.	4.4	0
228	Calcium-channel blockers and gastrointestinal motility: Basic and clinical aspects. , 1993, 60, 121-148.		37
229	Immunological Adverse Effects of Anticonvulsants. <i>Drug Safety</i> , 1993, 8, 235-250.	1.4	33
230	Control of intestinal motility by different receptor systems. <i>Pharmacological Research</i> , 1992, 25, 119-120.	3.1	3
231	Calcium antagonists and intestinal motility: Inhibition of muscular and nerve-mediated activities. <i>Pharmacological Research</i> , 1992, 26, 321.	3.1	0
232	Motility of rabbit proximal colon. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1746-1753.	1.1	5
233	Intraduodenal absorption of the new UF- heparin salt ITF 1057 in the conscious dog. <i>Thrombosis Research</i> , 1991, 62, 785-789.	0.8	19
234	Effect of Iron Succinyl-Protein Complexes on Gastrointestinal Motility in the Fasting Dog. <i>Digestion</i> , 1991, 50, 72-81.	1.2	8

#	ARTICLE	IF	CITATIONS
235	Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1991, 40, 149-153.	0.8	11
236	Effects of a New 1, 4-Dihydropyridine, Lacidipine, on Gastrointestinal Motility and Other Gastrointestinal Functions. <i>Pharmacology</i> , 1990, 41, 246-255.	0.9	6
237	Pharmacokinetics of the total triterpenic fraction of <i>Centella asiatica</i> after single and multiple administrations to healthy volunteers. A new assay for asiatic acid. <i>Journal of Ethnopharmacology</i> , 1990, 28, 235-241.	2.0	57
238	Regulation of intestinal motility by different muscarinic receptor subtypes. <i>European Journal of Pharmacology</i> , 1990, 183, 2191.	1.7	1
239	Variations in Gastric Tone Associated with Duodenal Motor Events After Activation of Central Emetic Mechanisms in the Dog. <i>Neurogastroenterology and Motility</i> , 1990, 2, 1-11.	1.6	12
240	Inhibitory Effects of DF 594, a New Antispasmodic Agent, on Intestinal Motility in the Dog. <i>Pharmacology</i> , 1989, 38, 374-380.	0.9	1
241	Relaxatory responses of canine proximal stomach to esophageal and duodenal distension. <i>Digestive Diseases and Sciences</i> , 1989, 34, 873-881.	1.1	53
242	Recent advances in the physiology and pharmacology of intestinal motility. <i>Pharmacological Research</i> , 1989, 21, 67-73.	3.1	8
243	Inhibitory effects of calcium channel blockers on intestinal motility in the dog. <i>European Journal of Pharmacology</i> , 1989, 168, 133-144.	1.7	22
244	Quantitative analysis of intestinal electrical spike activity by a new computerized method. <i>International Journal of Bio-medical Computing</i> , 1988, 22, 51-64.	0.5	14
245	A re-appraisal of the mode of action of 5-HT in inhibiting GABA-induced cholinergic contractions in the guinea-pig ileum. <i>European Journal of Pharmacology</i> , 1986, 127, 267-270.	1.7	3
246	Inhibitory action of capsaicin on cholinergic responses induced by GABA <sub>A</sub> agonists in the guinea-pig ileum. <i>European Journal of Pharmacology</i> , 1986, 128, 273-276.	1.7	4
247	Subsensitivity of enteric cholinergic neurones to $\alpha_2$ -adrenoceptors agonists after chronic sympathetic denervation. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1985, 329, 271-277.	1.4	19
248	Depression by morphine of the excitability of intrinsic inhibitory neurons in the guinea-pig colon. <i>European Journal of Pharmacology</i> , 1985, 115, 317-320.	1.7	18
249	Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety. , 0, , .		26